Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite α-Blocker Treatment in Patients With BPH: The ADDITION STUDY

Takeda, Masayuki; Nishizawa, Osamu; Gotoh, Momokazu; Yoshida, Masaki; Takahashi, Satoru; Masumori, Naoya

doi:10.1016/j.urology.2013.05.008

Cited by 40 publications

(48 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the number of enrolled patients was insufficient, the study was closed because of the smaller number of withdrawals than expected. Analysis for safety was done using 81 patients because 9 men M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 were excluded due to protocol violation and 4 never came back to the hospital after the randomization. Of them, 76 men (n = 38 in the tamsulosin-alone group and n = 38 in the mirabegron add-on group) completed the protocol treatment and provided a full analysis set.…”

Section: Patient Populationmentioning

confidence: 99%

See 1 more Smart Citation

A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Patient Populationmentioning

confidence: 99%

“…The effectiveness of anticholinergic agents was shown by large scale, well-designed randomized control clinical trials [2][3][4][5][6][7][8] . In real life clinical practice, we previously showed the efficacy of the combination therapy using an anticholinergic agent and α-blocker in patients with BPO and remaining OAB symptoms 9 .…”

Section: Introductionmentioning

confidence: 99%

A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the current study had a short treatment course, it seems likely that 4 weeks may be enough to produce significant improvement in the various outcome indices [14,25]. Data from clinical trials indicate that the percentage of patients who prematurely discontinue antimuscarinics is low.…”

Section: Discussionmentioning

confidence: 99%

Can We Decide the Optimal Initial Treatment for Male Lower Urinary Tract Symptoms Patients with Overactive Bladder by the Most Bothersome Symptom? A Randomized, Prospective, Open-Label Study

Yun

Kim

et al. 2014

Urol Int

View full text Add to dashboard Cite

Objectives: To compare the treatment outcome of tamsulosin 0.4 mg (TAM) with or without solifenacin 5 mg (SOL) for the most bothersome symptom in male lower urinary tract symptoms (LUTS) with overactive bladder (OAB). Subjects and Methods: Male LUTS/OAB (≥50 years) patients who had a total International Prostate Symptom Score (I-PSS) of ≥12, I-PSS urgency-related question of ≥2, and quality of life (QoL) of ≥3 points were enrolled. Patients who complained of storage symptoms as the most bothersome were included in the ‘storage' group. Patients who complained of voiding symptoms as the most bothersome were included in the ‘voiding' group. The change in the I-PSS was compared between the two groups 4 weeks after commencing treatment. Results: In the storage group, 172 were able to finish this study (TAM: 88, TAM + SOL: 84). The improvement of I-PSS and QoL with TAM + SOL was significantly greater than with TAM alone (p < 0.001). In the voiding group, 108 were able to finish the study (TAM: 54, TAM + SOL: 54). The improvement of I-PSS and QoL with TAM alone was significantly greater than with TAM + SOL (p < 0.001). Conclusions: The most bothersome symptom in male LUTS/OAB should be considered when choosing the appropriate medical treatment.

show abstract

“…70,71 It has also been used in combination therapy with a-blockers in patients with benign prostatic hyperplasia (BPH) and urgency/ urge urinary incontinence. 72 De novo or worsening of cognitive impairment has been described in elderly patients when taking imidafenacin, although it is reversible. 73 An experimental study by Yamamoto 74 was designed to assess the quantitative relationship between the central mAChR occupancy and cognitive impairment by oxybutynin and imidafenacin in Macaca mulatta monkeys using N-[11C] methyl-3-piperidyl benzilate and the Titration version of delayed matching to sample (T-DMS) task.…”

mentioning

confidence: 99%

Treatment of Overactive Bladder in Elderly Patients: Clinical Considerations

2015

Clinical Medicine Insights: Geriatrics

View full text Add to dashboard Cite

Overactive bladder (OAB) is a highly prevalent disorder among elderly and frail elderly patients, who are frequently polymedicated, suffer from kidney and liver failure and are susceptible to adverse events. Particular attention is, therefore, being given to efficacy and side effects of the treatment in patients older than 75 years. The introduction of newly developed drugs specifically designed for the treatment of OAB is opening new frontiers on this respect. The authors summarize the most recent evidence on this topic.

show abstract

Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite α-Blocker Treatment in Patients With BPH: The ADDITION STUDY

Cited by 40 publications

References 23 publications

A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction

A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction

Can We Decide the Optimal Initial Treatment for Male Lower Urinary Tract Symptoms Patients with Overactive Bladder by the Most Bothersome Symptom? A Randomized, Prospective, Open-Label Study

Treatment of Overactive Bladder in Elderly Patients: Clinical Considerations

Contact Info

Product

Resources

About